<p> ;</p>
<p><em>Updates on the trial of Pfizer-Biontech vaccines</em><br />
<a href="https://openlife.ng/">OpenLife Nigeria</a> reveals that the ongoing Phase 3 clinical trial of Pfizer/BioNTech&#8217;s coronavirus vaccine confirms its protection lasts at least six months after the second dose, the companies said.<br />
The question of how long vaccine protection lasts can only be answered once enough time has passed, and while six months of protection is a modest target, it&#8217;s longer than previously known. The study is continuing and future updates may reveal more about how long and how strong this protection is.<br />
The vaccine remains more than 91% effective against disease with any symptoms for six months, the companies said. And it appeared to be fully effective against the worrying B.1.351 variant of the virus, which is the dominant strain circulating in South Africa and which researchers feared had evolved to evade the protection of vaccines, the companies said.<br />
&#8220;The vaccine was 100% effective against severe disease as defined by the U.S. Centers for Disease Control and Prevention (CDC), and 95.3% effective against severe COVID-19 as defined by the <a href="https://openlife.ng/">U.S. Food and Drug Administration</a> (FDA),&#8221; Pfizer and BioNTech said in a joint statement.</p>
<p>On the updates <strong>on</strong> Wednesday, the companies said a small trial of volunteers aged12 to 15 showed 100% efficacy in that age group.<br />
&#8220;These data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA,&#8221; Albert Bourla, Pfizer&#8217;s chairman and chief executive officer, said in a statement. A BLA is an application for full approval. The vaccine currently has emergency use authorization, EUA, which falls short of full approval.<br />
&#8220;The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine&#8217;s overall effectiveness.&#8221;<br />
The company has been studying the vaccine in more than 46,000 volunteers and has noted 927 cases of confirmed Covid-19.<br />
&#8220;From the 927 confirmed symptomatic cases of COVID-19 in the trial, 850 cases of COVID-19 were in the placebo group and 77 cases were in the BNT162b2 group, corresponding to vaccine efficacy of 91.3%,&#8221; it said.<br />
&#8220;Thirty-two cases of severe disease, as defined by the CDC, were observed in the placebo group versus none in the BNT162b2 vaccinated group, indicating that the vaccine was 100% efficacious in this analysis against severe disease by the CDC definition. Twenty-one cases, as defined by the FDA, were observed in the placebo group versus one case in the BNT162b2 vaccinated group, indicating 95.3% efficacy by the FDA definition.&#8221;</p>
<p>These definitions matter. The FDA&#8217;s definition of severe disease included a raised respiratory rate indicating respiratory distress; raised heart rate, an oxygen saturation level of 93% or lower; respiratory failure severe enough to need additional oxygen or ventilation; a blood pressure drop indicating shock; significant kidney, liver or neurological dysfunction, admission to an intensive care unit or death.<br />
CDC&#8217;s definition includes a blood oxygen level of 94% or lower and an x-ray finding of lung infiltrates &#8212; an indication of pneumonia &#8212; of greater than 50%<br />
The most common adverse events were pain at the injection site, fatigue and headache.<br />
&#8220;In South Africa, where the B.1.351 lineage is prevalent and 800 participants were enrolled, nine cases of COVID-19 were observed, all in the placebo group, indicating vaccine efficacy of 100%,&#8221; the company said.<br />
&#8220;Vaccine safety has now been evaluated in more than 44,000 participants aged 16 years and older with more than 12,000 vaccinated participants having at least six months of follow-up after their second dose.&#8221;<br />
Meanwhile, Pfizer Incorporated has projected about $15 billion in revenue this year from the Covid-19 vaccine it developed with BioNTech SE, but the shares fell amid questions about the durability of the market for the shot.<br />
Company officials led by Chief Executive Albert Bourla said on a conference call that the vaccine looks capable of taking on new variants, its price may increase and new products using its messenger RNA technology are on the way. Still, the shares fell as much as 4.3% and were down 2.2% at 2:10 p.m Tuesday in New York.<br />
The first of the Western coronavirus shots cleared for use, the <a href="https://www.bloomberg.com/">Pfizer-BioNTech</a> vaccine will soon face competition from more entrants, including from Johnson &; Johnson and Novavax Inc. that are poised for authorization. New virus variants may also require additional vaccines or reformulated booster shots for protection.</p>

“I Fought For My Daughter, Let’s Move On” — Davido Drops Custody Case After Court…
“My Wife Taught Me How To Love Her” — Pastor Kingsley Okonkwo Spills Truth About…
“You Bought 2 Cars for Your Mom & Forgot Your Dad” – Radiogad Slams Regina…
Confusion Over 2027 Election Timetable OpenLife Nigeria reports that confusion has enveloped the…
“I Didn’t Kneel, I Won’t Kneel” — Agoro Sparks Online Wedding Debate Tradition OpenLife Nigeria…
Pastor And Former Big Brother Naija Contestant Ignite Firestorm Over LGBTQ+ And Faith OpenLife…
This website uses cookies.